Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of Avexitide

Rhea-AI Summary

Amylyx Pharmaceuticals (NASDAQ: AMLX) announced that it will host a conference call and webcast on Wednesday, July 10, 2024, at 8:00 a.m. ET to discuss its acquisition of avexitide from Eiger BioPharmaceuticals.

The conference call can be accessed by dialing +1 (800) 836-8184 in the U.S. and Canada or +1 (646) 357-8785 internationally, 10 minutes before the start time, and by asking to join the Amylyx Pharmaceuticals call.

A live audio webcast will be available in the Investor section of the Amylyx website and can be replayed for 90 days post-event.

Positive

• Amylyx Pharmaceuticals' acquisition of avexitide could potentially enhance its product portfolio and market presence.

Negative

• The acquisition could impose financial strain on Amylyx Pharmaceuticals.
• The integration of avexitide could present operational challenges.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that Amylyx’ management team will host a conference call and webcast tomorrow, Wednesday, July 10, 2024, at 8:00 a.m. ET to discuss the acquisition of avexitide from Eiger BioPharmaceuticals.

To access the conference call, please dial +1 (800) 836-8184 (U.S. and Canada) or +1 (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Amylyx Pharmaceuticals call. A live audio webcast of the call will be available under “Events and Presentations” in the Investor section of the Company’s website, https://investors.amylyx.com/news-events/events, and will be available for replay for 90 days following the event.

About Amylyx Pharmaceuticals

Amylyx is committed to the discovery and development of new treatment options for communities with high unmet needs, including people living with serious and fatal diseases. Since its founding, Amylyx has been guided by science to address unanswered questions, keeping communities at the heart and center of all decisions. Amylyx is headquartered in Cambridge, Massachusetts. For more information, visit amylyx.com and follow us on LinkedIn and X (formerly Twitter). For investors, please visit investors.amylyx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240709000861/en/

Media

Amylyx Media Team

+1 (857) 799-7274

amylyxmediateam@amylyx.com

Investors

Lindsey Allen

+1 (857) 320-6244

Investors@amylyx.com

Source: Amylyx Pharmaceuticals, Inc.

FAQ

When will Amylyx Pharmaceuticals discuss the acquisition of avexitide?

Amylyx Pharmaceuticals will discuss the acquisition of avexitide on Wednesday, July 10, 2024, at 8:00 a.m. ET during a conference call and webcast.

How can I access the Amylyx Pharmaceuticals conference call about the avexitide acquisition?

You can access the conference call by dialing +1 (800) 836-8184 in the U.S. and Canada or +1 (646) 357-8785 internationally at least 10 minutes before the start time and asking to join the Amylyx Pharmaceuticals call.

Where can I find the live audio webcast of the Amylyx conference call?

The live audio webcast will be available under 'Events and Presentations' in the Investor section of the Amylyx website and will be replayable for 90 days following the event.

What is the significance of Amylyx Pharmaceuticals acquiring avexitide?

The acquisition of avexitide is significant as it may enhance Amylyx Pharmaceuticals' product portfolio and market presence.

What potential challenges does Amylyx face with the avexitide acquisition?

Amylyx Pharmaceuticals may face financial strain and operational challenges during the integration of avexitide.